Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals

• New PRAXBIND.com tool enables physicians and patients to quickly locate local institutions where   PRAXBIND is available

Source: Boehringer Ingelheim Press Releases - March 7, 2016 Category: Research Source Type: news